TCT-690 Prognostic Value of Body Surface Area on Clinical Outcomes after Transcatheter Aortic Valve Replacement  by Arsalan, Mani et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B281for implantations in aortic position. Histological analyses showed a
debris capture rate of 93% in any or both ﬁlters. Finding debris in the
proximal ﬁlter was more common (100%) than in the distal ﬁlter (86%).
Acute thrombus was the most common type of debris, captured in 64%
of theﬁlters. In 28%, valve and arterial wall tissue and calciﬁcationwere
also found, with the percentage of debris higher in the proximal ﬁlter.
Organized thrombus was found in 7%; foreign material was also found
in 7% of all cases, but only in the distal ﬁlter.
CONCLUSIONS Histopathological analyses showed high overall debris
capture rates, with higher prevalence of thrombus over valve and arterial
wall tissue, calciﬁcation and foreign material. Procedural stroke rate was
0%. Further investigation (especially histopathological) is needed to
investigate the characterization of the debris and to differentiate between
valve-in-valve procedures in the aortic and mitral position.
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BACKGROUND Transapical access for transcatheter aortic valve im-
plantation (TA-TAVI) has become a routine procedure for patients at
high surgical risk and is a valid alternative to transfemoral TAVI.
Transapical access has seen little standardization of technique due to
the absence of automated preclosure and carries a risk for bleeding
complications. Here we describe the use of a novel device designed to
facilitate safe and reliable, automated transmyocardial access and
closure during structural heart interventions such as TA-TAVI.
METHODS A total of 34 patients in 1 Dutch and 4 German centers
underwent transapical TAVI through mini-thoracotomies using the
Permaseal closure device (STASIS trial). All patients received Edwards
Sapien 3 or Sapien XT valves. The closure device consists of 8 poly-
propylene anchors connected by a braided polyester pre-tied suture
allowing for the passage of sheaths up to 30 Fr. Anchors are me-
chanically deployed into the myocardial tissue near the anatomical
apex using an over the wire system. After removal of the TAVI sheath,
hemostasis is achieved by advancement of the pre-tied suture, and
approximation of the anchors without the need for fast pacing. All
patients were prospectively followed for 30 and 90 days.
RESULTS The Permaseal apical closure device was successfully
deployed in all patients. Hemostasis was achieved with no or only one
additional pledgeted suture after sheath removal and anchor approxi-
mation by closing of the pre-tied suture in 94.1% of patients. In 2 pa-
tients additional sutures were applied to resolve ongoing bleeding from
the apical access site. Two patients (one roll-in patient and one protocol
deviation) were excluded from the efﬁcacy analysis. Three patients
(8.8%) required transfusion of more than 2 units either peri-proce-
durally or prior to discharge. Mean operation time was 86  22.5 min
and mean length of stay in the hospital was 9.53.2 days. Pulsatile
bleeding was not reported and re-intervention was not required for any
patient following the surgical procedure, at hospital discharge, 30-day
follow-up or 90-day follow-up. No patients died during 30 day follow-
up, however one patient died on day 37 from complications related to
hip replacement surgery. No patients suffered strokes or myocardial
infarctions during the 90 day follow-up period.
CONCLUSIONS The Permaseal device allows for minimally invasive
reproducible access and closure of the left ventricular apex for TA
TAVI. The device complies with the beating heart and shows no
interference with wall motion while leaving only little foreign mate-
rial behind. This access and closure approach may help to reduce OR
time, abate blood loss, and simplify transapical access for TAVI.
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BACKGROUND POL-TAVI is an on-going all-comer registry enrolling
all TAVI procedures in Poland since 2009. Within the registry baseline
clinical, imaging and procedural data as well as in-hospital, early (30
days) and long-term (6 and 12 months) outcomes are prospectively
registered and reported yearly. Aim of the study was to evaluate the
outcomes of TAVI patients presenting with chronic anemia.
METHODS The registry enrolled 381 patients treated in 2013 (43,6%
males, mean age of 78,757,4 years, logistic EuroScore 20,214,5, STS
8,528,3). Anemia was diagnosed based on WHO deﬁnition (Hb <13 g/
dL for men and <12 g/dL for women).
RESULTS There were 184 (47,5%) patients with anemia. In comparison to
patients without anemia they were signiﬁcantly older (79,77,2 vs.
77,97,4, p<0.03). Both groups had comparable Log EuroScore (21,114,5
vs. 19,514,5, p¼0.16), NYHA and CCS class. Patients with anemia have
moreoften creatinine level> 200umol/l (10,87 vs. 3.6%, p<0.01) and lower
GFR (50,319,9 vs. 59,419,2mL/min, p<0,001) on admission. The groups
didnotdiffer in the frequencyof chronicdialysisprior toAVaswell as acute
kidney injury post TAVI (14,67% vs. 9,33%, p¼0.11). Patients with anemia
requiredmore blood transfusion post TAVI (49,18% vs. 27,2%, p<0.001). A
trend to higher mortality in a group of patients with anemia on admission
could be observed at 1 month (12,20 vs. 8,9%, p¼0,36), 6 months (21,97 vs.
13,9%, p¼0,11) which became signiﬁcant at 12 months (34,31 vs. 17,43%,
P<0,01). In logistic regression analysis presence of anemia was an inde-
pendent predictor of death at 1 year [OR 95%CI 2,47 (1,32;4,77), p¼0,0048]
similarly to drop in Hb level during hospitalization [OR 95% CI 0,82
(0,67;0,99), p¼0.039 for decrease of by 1 g/dL]. The need of transfusion
increased the risk of death 3,2 times (OR 95% CI 3,23 (1,70;6,32), p<0,002).
CONCLUSIONS Chronic anemia is present in almost 48% of patients un-
dergoing TAVI and associated with 2,5-fold higher mortality in 12 months
follow-up. Signiﬁcant drop in hemoglobin levels and need of blood trans-
fusion also signiﬁcantly increased the short and long term mortality.
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BACKGROUND An inverse association between bodymass index (BMI)
andmortality in patients after Transcatheter Aortic Valve Replacement
(TAVR) has been reported. This ’obesity paradox’ is controversial,
however, because not all TAVR series have demonstrated such a rela-
tionship betweenBMI andmortality. Body surface area (BSA)might be a
more suitable marker to identify patients at risk for mortality following
TAVR, but little is currently known about its prognostic value.
METHODS This prospective, observational study consisted of 917
consecutive patients undergoing TAVR at our center from 2011-
2014. The association between BSA and mortality (at 30-days and
1-year) was assessed using restricted cubic spline functions in a
propensity-adjusted (by Society of Thoracic Surgeons’ risk factors)
logistic and Cox proportional model, respectively.
RESULTS Mean follow-up time was 141 days. Throughout the study
period, 152 (16.5%) patients died; 72 (7.9%) patients died within 30
B282 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5days of TAVR. After risk-adjustment, the association between BSA and
mortality was not signiﬁcant during either follow-up window (30-day
p ¼ 0.249; 1-year p ¼ 0.253; see Figure), but showed a trend to higher
mortality in patients with very low BSA.
CONCLUSIONS No signiﬁcant association between BSA and mortality
after TAVR was detected. While there was a trend towards increased
mortality in patients with lower BSA, larger studies are needed to
provide deﬁnitive answers. As with BMI, BSA might be of prognostic
value for patients undergoing TAVR.
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BACKGROUND Valve types for transcatheter aortic valve implanta-
tion (TAVI) have undergone rapid evolution. The new balloon-
expandable Edwards Sapien-3 (S3) valve offers several novel features
to prevent or reduce typical TAVI-related problems such as para-
valvular leaks (PVLs) and vascular complications. The aim of this
study was to investigate the potential differences in the clinical
outcome compared to its predecessor Sapien XT (SXT).
METHODS We analyzed n¼400 consecutive patients undergoing TAVI
at our institution from 2012-2015 using balloon-expandable Edwards
Sapien-3 (n¼200, 61% transfemoral (TF), 27.5% transaortic (TAo), 11.5%
transapical (TA)) and Sapien XT (n¼200, 52.5% TF, 27.5% TAo and
20.0% TA) prostheses. The change in valve type was in 02/2014. All
patients were available for complete retrospective analyses. The
severity of paravalvular AR was evaluated with echocardiography 7d
after TAVI. The outcomewas analyzed according to the VARC-2 criteria.
RESULTS Comparison of both baseline characteristics of both groups
showedahigher surgical risk score for theSapien-3 group (meanSTS score S3
8.6% % (7.1) vs SXT 6.4% % (4.1)) and a higher rate of previous cardiac
surgery in SXT group (S3 30.0% vs. SXT 48.5%, p<0.001). No differences
between groups could be detected in mean age, sex, previous pacemaker
implantations, LV function, cardiovascular risk factors, COPD, and pAVK.
Despite higher surgical risk of the S3patientswe couldnot detect a difference
in 30dmortality betweenboth groups (S3 7.5%vs. SXT7.0%). Postprocedural
echocardiographyrevealed lessmildandmoderatePVLs inS3 (0%moderate,
18.8%mild AR) patients than SXT patients (4.6%moderate and 40.8%mild,
p<0.001). In addition, postdilatationwas carried outmore frequently in SXT
patients (46.0% pts vs. 23.0% pts, p<0.001). However, the use of the S3
prosthesiswasassociatedwith increased risk fornewconductiondisturbance
requiring new pacemaker implantation (S3 10.8% vs. SXT 5.2%, p¼0.05).
CONCLUSIONS Theseﬁndings indicate that theuseof theEdwardsSapien-
3device leads to reducednumbersof signiﬁcantPVLs.Yetwecoulddetect an
increased need for new pacemaker implantation in S3 patients. Future in-
vestigations aim to analyze the potential effects on long-term survival.
CATEGORIES STRUCTURAL: Valvular Disease: AorticTCT-692
The effect of balloon predilatation in TAVI on long-term mortality
Konstantinos Stathogiannis,1 Konstantinos Toutouzas,2
Maria Drakopoulou,3 George Latsios,4 Andreas Synetos,4
Constantina Aggeli,1 Odysseas Kaitozis,4 Georgios Trantalis,5
Antonios Mastrokostopoulos,6 Ulrich J. Gerckens,7 Eberhard Grube,8
Dimitrios Tousoulis9
1Hippokration Hospital, Athens, Greece; 2First Department of
Cardiology, Holargos, Greece; 3Hippokration, Athens, Attica;
4Hippokration Hospital, Athens, Attica; 5First Department of
Cardiology, Athens Medical School, Athens, Greece; 6Hippokration,
Athens, Attika; 7Hospital St Petrus, Heartcenter Rhein-Ahr, Bonn,
Germany; 8University Hospital Bonn, Bonn, Germany; 9Hippokratio
Hospital, Athens, Greece
BACKGROUND Direct transcatheter aortic valve implantation (TAVI)
has shown to be safe and feasible with a similar success rate to TAVI
with prior balloon aortic valvuloplasty (BAV). The aim of this study
was to evaluate the effect of direct TAVI on long-term mortality with a
self-expanding bioprosthesis.
METHODS Prospectively collected data before and after TAVI from
two high-volume centers were retrospectively analyzed in all pa-
tients. Primary clinical end-point was all-cause mortality at 1 year. All
outcomes were evaluated according to the VARC-2 criteria.
RESULTS We included 210 patients in the study (120 patients for non-
direct TAVI and 90patients for direct TAVI). Both groups had similar 1-year
mortality rates (15% in non-direct versus 11% in direct, p¼0.5). No major
differenceswereobserved concerning cardiovascular death (3%versus 2%,
p¼0.9), stroke (3% versus 5%, p¼0.4) and acute myocardial infarction (2%
versus0%, p¼0.2), in non-direct anddirect TAVI groups respectively in the
mid-term. The direct grouphad lessmoderate/severe paravalvular leakage
(PVL) post TAVI compared to the non-direct group (8% vs 27%, p<0.01). At
univariate analysis, predictors formortalitywere: BAVbefore TAVI (p¼0.2,
OR: 1.71, 95%CI: 0.742-3.939), logEuroscore (p<0.044, OR: 1.046, 95%CI:
1.001-1.093), failure to achieve device success (p¼0.143, OR: 1.795, 95%CI:
0.821-3.926) and the interventricular septum thickness (p<0.048, OR:
1.249, 95%CI: 1.002-1.555). Atmultivariate analysis, independent predictor
of mortality was logEuroscore (p<0.035, OR: 1.058, 95%CI: 1.004-1.114).
CONCLUSIONS Direct TAVI is safe and comparable outcomes are
achieved with the current practice of TAVI with balloon aortic val-
vuloplasty. Further studies are necessary to assess the long-term
mortality and effect on PVL of direct TAVI.
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BACKGROUND Transcutaneous aortic valve implantation (TAVI)
signiﬁcantly improves the prognosis of inoperable patients with severe
aortic stenosis and appears to be equivalent to surgery in high-risk
patients. However, limitations of ﬁrst-generation devices regarding
repositioning and optimization of placement can result in complica-
tions and hence increase mortality. Therefore, it was the aim of this
study to evaluate the performance of a resheathable and repositionable
self-expanding TAVI system in high risk patients with aortic stenosis.
METHODS This prospective, single arm, multicentre study evaluated
the safety and efﬁcacy of the PorticoTM Transcatheter Aortic Valve
Implantation System. Between March 2012 and April 2014 102 patients
(97% Female; Mean Age: 845 years; STS Score: 6.23.5, logistic
EuroScore: 16.77.5 %) were treated at 7 sites in the UK, and Germany
using the 18F Portico Delivery System with a 23 or 25mm Portico
Valve. Patients were followed post procedure at 30, 90, 180 days and
1 year. Adverse events were categorized by VARC deﬁnitions and
adjudicated by an independent events committee. Echocardiography
was evaluated by an independent laboratory.
